Table 1. Patient Demographic Characteristics, Medical History, and COVID-19–Related Information.
| Patient No. | Age range, y | Medical history | COVID-19 symptom | Chest radiograph result | No. of days from positive result to thrombotic event (serological test used) |
|---|---|---|---|---|---|
| 1 | 36-40 | None | None | Normal | 40 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 2 | 36-40 | HPT | None | Normal | 19 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 3 | 41-45 | None | Diarrhea | Normal | 36 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 4 | 46-50 | None | None | Normal | 8 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 5 | 36-40 | None | None | Normal | 24 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 6 | 36-40 | None | None | Normal | 76 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 7 | 41-45 | None | None | Normal | 50 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 8 | 36-40 | None | None | Normal | 91 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 9 | 31-35 | None | None | Normal | 84 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 10 | 41-45 | None | None | Normal | 42 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 11 | 41-45 | None | None | Normal | 55 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 12 | 46-50 | None | None | Normal | 0 (Elecsys Anti-SARS-CoV-2 assay; Roche)a |
| 13 | 46-50 | HLD | None | Normal | 96 (Elecsys Anti-SARS-CoV-2 assay; Roche) |
| 14 | 46-50 | HPT | None | Normal | 130 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 15 | 31-35 | None | None | Normal | 108 Architect SARS-CoV-2 IgG assay; (Abbott) |
| 16 | 41-45 | Diabetes | None | Normal | 54 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 17 | 36-40 | HPT | None | Normal | 64 (Architect SARS-CoV-2 IgG assay; Abbott) |
| 18 | 41-45 | HLD | None | Normal | 113 (Architect SARS-CoV-2 IgG assay; Abbott) |
Abbreviations: HLD, hyperlipidemia; HPT, hypertension.
a
Serological test performed during acute stroke hospitalization.